• 1
    McLendon MK, Apicella MA, Allen LA. Francisella tularensis: taxonomy, genetics, and immunopathogenesis of a potential agent of biowarfare. Annu Rev Microbiol 2006; 60:16785.
  • 2
    Sjostedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci 2007; 1105:129.
  • 3
    Tarnvik A, Chu MC. New approaches to diagnosis and therapy of tularemia. Ann N Y Acad Sci 2007; 1105:378404.
  • 4
    Thomas LD, Schaffner W. Tularemia pneumonia. Infect Dis Clin North Am 2010; 24:4355.
  • 5
    Dennis DT, Inglesby TV, Henderson DA et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001; 285:276373.
  • 6
    Conlan JW. Tularemia vaccines: recent developments and remaining hurdles. Future Microbiol 2011; 6:391405.
  • 7
    Oyston PC. Francisella tularensis vaccines. Vaccine 2009; 27(Suppl 4):D4851.
  • 8
    Elkins KL, Cowley SC, Bosio CM. Innate and adaptive immunity to Francisella. Ann N Y Acad Sci 2007; 1105:284324.
  • 9
    Elkins KL, Rhinehart-Jones TR, Culkin SJ, Yee D, Winegar RK. Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect Immun 1996; 64:328893.
  • 10
    Wu TH, Hutt JA, Garrison KA, Berliba LS, Zhou Y, Lyons CR. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A. Infect Immun 2005; 73:264454.
  • 11
    Leiby DA, Fortier AH, Crawford RM, Schreiber RD, Nacy CA. In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infect Immun 1992; 60:849.
  • 12
    Stenmark S, Sunnemark D, Bucht A, Sjostedt A. Rapid local expression of interleukin-12, tumor necrosis factor alpha, and gamma interferon after cutaneous Francisella tularensis infection in tularemia-immune mice. Infect Immun 1999; 67:178997.
  • 13
    Elkins KL, Bosio CM, Rhinehart-Jones TR. Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infect Immun 1999; 67:60027.
  • 14
    Drabick JJ, Narayanan RB, Williams JC, Leduc JW, Nacy CA. Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine. Am J Med Sci 1994; 308:837.
  • 15
    Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun 1991; 59:29228.
  • 16
    Foshay L. Tularemia: a summary of certain aspects of disease including methods for early diagnosis and the results of serum treatment in 600 patients. Medicine 1940; 19:183.
  • 17
    Fulop M, Mastroeni P, Green M, Titball RW. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 2001; 19:446572.
  • 18
    Kirimanjeswara GS, Golden JM, Bakshi CS, Metzger DW. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 2007; 179:5329.
  • 19
    Rhinehart-Jones TR, Fortier AH, Elkins KL. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect Immun 1994; 62:312937.
  • 20
    Stenmark S, Lindgren H, Tarnvik A, Sjostedt A. Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica. Microb Pathog 2003; 35:7380.
  • 21
    Sebastian S, Dillon ST, Lynch JG et al. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity. Infect Immun 2007; 75:2591602.
  • 22
    Kirimanjeswara GS, Olmos S, Bakshi CS, Metzger DW. Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis. Immunol Rev 2008; 225:24455.
  • 23
    Klimpel GR, Eaves-Pyles T, Moen ST et al. Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody. Vaccine 2008; 26:687482.
  • 24
    Valentino MD, Maben ZJ, Hensley LL, Woolard MD, Kawula TH, Frelinger JA, Frelinger JG. Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets. Immunology 2011; 132:34860.
  • 25
    Conlan JW, Shen H, Webb A, Perry MB. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 2002; 20:346571.
  • 26
    Fulop M, Manchee R, Titball R. Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 1995; 13:12205.
  • 27
    Fulop M, Manchee R, Titball R. Role of two outer membrane antigens in the induction of protective immunity against Francisella tularensis strains of different virulence. FEMS Immunol Med Microbiol 1996; 13:2457.
  • 28
    Lu Z, Roche MI, Hui JH, Unal B, Felgner PL, Gulati S, Madico G, Sharon J. Generation and characterization of hybridoma antibodies for immunotherapy of tularemia. Immunol Lett 2007; 112:92103.
  • 29
    Savitt AG, Mena-Taboada P, Monsalve G, Benach JL. Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy. Clin Vaccine Immunol 2009; 16:41422.
  • 30
    Khlebnikov VS, Vetchinin SS, Grechko GK et al. The preventive activity of monoclonal antibodies specific to the lipopolysaccharide of Francisella tularensis. Zh Mikrobiol Epidemiol Immunobiol 1992; 9–10:6770.
  • 31
    Li J, Ryder C, Mandal M et al. Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS. Microbiology 2007; 153:314153.
  • 32
    Sebastian S, Pinkham JT, Lynch JG, Ross RA, Reinap B, Blalock LT, Conlan JW, Kasper DL. Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis. Vaccine 2009; 27:597605.
  • 33
    Gunn JS, Ernst RK. The structure and function of Francisella lipopolysaccharide. Ann N Y Acad Sci 2007; 1105:20218.
  • 34
    Prior JL, Prior RG, Hitchen PG, Diaper H, Griffin KF, Morris HR, Dell A, Titball RW. Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis. J Med Microbiol 2003; 52:84551.
  • 35
    Thirumalapura NR, Goad DW, Mort A, Morton RJ, Clarke J, Malayer J. Structural analysis of the O-antigen of Francisella tularensis subspecies tularensis strain OSU 10. J Med Microbiol 2005; 54:6935.
  • 36
    Vinogradov EV, Shashkov AS, Knirel YA, Kochetkov NK, Tochtamysheva NV, Averin SF, Goncharova OV, Khlebnikov VS. Structure of the O-antigen of Francisella tularensis strain 15. Carbohydr Res 1991; 214:28997.
  • 37
    Wang Q, Shi X, Leymarie N, Madico G, Sharon J, Costello CE, Zaia J. A typical preparation of Francisella tularensis O-antigen yields a mixture of three types of saccharides. Biochemistry 2011; 50:1094150.
  • 38
    Murphy K, Travers P, Walport M, Janeway C. Janeway’s immunobiology, 7th edn. New York: Garland Science, 2008.
  • 39
    Roche MI, Lu Z, Hui JH, Sharon J. Characterization of monoclonal antibodies to terminal and internal O-antigen epitopes of Francisella tularensis lipopolysaccharide. Hybridoma 2011; 30:1928.
  • 40
    Khlebnikov VS, Golovlev IR, Tokhtamysheva NV, Averin SF, Kulevatskii DP, Grechko GK, Averina AA, Vetchinin SS. The determination of the antigenic determinant of protective monoclonal antibodies specific to the Francisella tularensis lipopolysaccharide. Zh Mikrobiol Epidemiol Immunobiol 1993; Jan-Feb:838.
  • 41
    Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 1980; 40:71721.
  • 42
    Schlimok G, Gottlinger H, Funke I, Swierkot S, Hauser H, Riethmuller G. In vivo and in vitro labelling of epithelial tumor cells with anti 17-1A monoclonal antibodies in bone marrow of cancer patients. Hybridoma 1986; 5(Suppl 1):S16370.
  • 43
    Bakshi CS, Malik M, Mahawar M et al. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 2008; 26:527688.
  • 44
    Cisar J, Kabat EA, Dorner MM, Liao J. Binding properties of immunoglobulin combining sites specific for terminal or nonterminal antigenic determinants in dextran. J Exp Med 1975; 142:43559.
  • 45
    Ziegler T, Kovac P, Glaudemans CP. A synthetic heptasaccharide reveals the capability of a monoclonal antibody to read internal epitopes of a polysaccharide antigen. Carbohydr Res 1990; 203:25363.
  • 46
    Vyas NK, Vyas MN, Chervenak MC, Johnson MA, Pinto BM, Bundle DR, Quiocho FA. Molecular recognition of oligosaccharide epitopes by a monoclonal Fab specific for Shigella flexneri Y lipopolysaccharide: X-ray structures and thermodynamics. Biochemistry 2002; 41:1357586.
  • 47
    Villeneuve S, Souchon H, Riottot MM et al. Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity. Proc Natl Acad Sci USA 2000; 97:84338.
  • 48
    Sharon J, Kabat EA, Morrison SL. Immunochemical characterization of binding sites of hybridoma antibodies specific for alpha (1[RIGHTWARDS ARROW]6) linked dextran. Mol Immunol 1982; 19:37588.
  • 49
    Rose DR, Przybylska M, To RJ, Kayden CS, Oomen RP, Vorberg E, Young NM, Bundle DR. Crystal structure to 2·45 A resolution of a monoclonal Fab specific for the Brucella A cell wall polysaccharide antigen. Protein Sci 1993; 2:110613.
  • 50
    Padlan EA, Kabat EA. Model-building study of the combining sites of two antibodies to alpha (1[RIGHTWARDS ARROW]6)dextran. Proc Natl Acad Sci USA 1988; 85:68859.
  • 51
    Oomen RP, Young NM, Bundle DR. Molecular modeling of antibody–antigen complexes between the Brucella abortus O-chain polysaccharide and a specific monoclonal antibody. Protein Eng 1991; 4:42733.
  • 52
    Nashed EM, Perdomo GR, Padlan EA, Kovac P, Matsuda T, Kabat EA, Glaudemans CP. Binding characteristics of IgA 16.4.12E, a monoclonal antibody with specificity for the nonreducing terminal epitope of alpha-(1[RIGHTWARDS ARROW]6)-dextrans. Comparisons between IgA hybridoma 16.4.12E and myeloma W3129. J Biol Chem 1990; 265:20699707.
  • 53
    Glaudemans CP, Kovac P, Rao AS. The subsites of monoclonal anti-dextran IgA W3129. Carbohydr Res 1989; 190:26777.
  • 54
    Carlin NI, Bundle DR, Lindberg AA. Characterization of five Shigella flexneri variant Y-specific monoclonal antibodies using defined saccharides and glycoconjugate antigens. J Immunol 1987; 138:441927.
  • 55
    Kim TH, Pinkham JT, Heninger SJ, Chalabaev S, Kasper DL. Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine. J Infect Dis 2012; 205:105665.